Sasanlimab

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124058

2206792-50-7

C124058

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.

Sasanlimab

LZZ0IC2EWP

SASANLIMAB

Sasanlimab

WHO 11161

PF-06801591

Anti-PD-1 PF-06801591

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C94697

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Sasanlimab

Sasanlimab

Anti-PD-1 Checkpoint Inhibitor PF-06801591

776395

CL502495

776395

776395

Sasanlimab

Thesaurus:C124058

Sasanlimab

Pharmacologic Substance

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124946

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129820